Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Descarcare Prospect (PIL)
17-12-2021

Ingredient activ:

lenalidomide hydrochloride monohydrate

Disponibil de la:

Krka, d.d., Novo mesto 

Codul ATC:

L04AX04

INN (nume internaţional):

lenalidomide

Grupul Terapeutică:

Immunosuppressants

Zonă Terapeutică:

Multiple Myeloma; Lymphoma, Follicular

Indicații terapeutice:

Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).Multiple myelomaLenalidomide krka d.d. Novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Lenalidomide krka d.d. Novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Lenalidomide krka d.d. Novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Follicular lymphomaLenalidomide krka d.d. Novo mesto in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).

Rezumat produs:

Revision: 3

Statutul autorizaţiei:

Authorised

Data de autorizare:

2021-02-11

Prospect

                                79
B. PACKAGE LEAFLET
80
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LENALIDOMIDE KRKA D.D. NOVO MESTO 2.5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 7.5 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 10 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 15 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 20 MG HARD CAPSULES
LENALIDOMIDE KRKA D.D. NOVO MESTO 25 MG HARD CAPSULES
lenalidomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lenalidomide Krka d.d. Novo mesto is and what it is used for
2.
What you need to know before you take Lenalidomide Krka d.d. Novo
mesto
3.
How to take Lenalidomide Krka d.d. Novo mesto
4.
Possible side effects
5.
How to store Lenalidomide Krka d.d. Novo mesto
6.
Contents of the pack and other information
1.
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS AND WHAT IT IS USED FOR
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS
Lenalidomide Krka d.d. Novo mesto contains the active substance
‘lenalidomide’. This medicine
belongs to a group of medicines which affect how your immune system
works.
WHAT LENALIDOMIDE KRKA D.D. NOVO MESTO IS USED FOR
Lenalidomide Krka d.d. Novo mesto is used in adults for:
-
Multiple myeloma
-
Follicular lymphoma
MULTIPLE MYELOMA
Multiple myeloma is a type of cancer which affects a certain kind of
white blood cell, called the
plasma cell. These cells collect in the bone marrow and divide,
becoming out of control. This can
damage the bones and kidneys.
Multiple myeloma generally c
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules
Lenalidomide Krka d.d. Novo mesto 25 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains lenalidomide hydrochloride monohydrate
equivalent to 2.5 mg, 5 mg,
7.5 mg, 10 mg, 15 mg, 20 mg or 25 mg lenalidomide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule)
Lenalidomide Krka d.d. Novo mesto 2.5 mg hard capsules
Capsule cap is green, capsule body is green with imprinted black mark
2.5. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 4, length 14
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 5 mg hard capsules
Capsule cap is blue, capsule body is blue with imprinted black mark 5.
Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 2, length 18
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 7.5 mg hard capsules
Capsule cap is brown, capsule body is brown with imprinted white mark
7.5. Capsule content is white
to yellow white or to brown white powder. Hard capsule size: 1, length
19 ± 1 mm.
Lenalidomide Krka d.d. Novo mesto 10 mg hard capsules
Capsule cap is green, capsule body is brown with imprinted white mark
10. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 0, length 21
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 15 mg hard capsules
Capsule cap is brown, capsule body is blue with imprinted black mark
15. Capsule content is white to
yellow white or to brown white powder. Hard capsule size: 2, length 18
± 1 mm.
Lenalidomide Krka d.d. Novo mesto 20 mg hard capsules
Capsule cap is green, capsule body is blue with imprinted black mark
20
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 17-12-2021
Raport public de evaluare Raport public de evaluare bulgară 31-08-2021
Prospect Prospect spaniolă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 17-12-2021
Raport public de evaluare Raport public de evaluare spaniolă 31-08-2021
Prospect Prospect cehă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 17-12-2021
Raport public de evaluare Raport public de evaluare cehă 31-08-2021
Prospect Prospect daneză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 17-12-2021
Raport public de evaluare Raport public de evaluare daneză 31-08-2021
Prospect Prospect germană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului germană 17-12-2021
Raport public de evaluare Raport public de evaluare germană 31-08-2021
Prospect Prospect estoniană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 17-12-2021
Raport public de evaluare Raport public de evaluare estoniană 31-08-2021
Prospect Prospect greacă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 17-12-2021
Raport public de evaluare Raport public de evaluare greacă 31-08-2021
Prospect Prospect franceză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 17-12-2021
Raport public de evaluare Raport public de evaluare franceză 31-08-2021
Prospect Prospect italiană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 17-12-2021
Raport public de evaluare Raport public de evaluare italiană 31-08-2021
Prospect Prospect letonă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 17-12-2021
Raport public de evaluare Raport public de evaluare letonă 31-08-2021
Prospect Prospect lituaniană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 17-12-2021
Raport public de evaluare Raport public de evaluare lituaniană 31-08-2021
Prospect Prospect maghiară 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 17-12-2021
Raport public de evaluare Raport public de evaluare maghiară 31-08-2021
Prospect Prospect malteză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 17-12-2021
Raport public de evaluare Raport public de evaluare malteză 31-08-2021
Prospect Prospect olandeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 17-12-2021
Raport public de evaluare Raport public de evaluare olandeză 31-08-2021
Prospect Prospect poloneză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 17-12-2021
Raport public de evaluare Raport public de evaluare poloneză 31-08-2021
Prospect Prospect portugheză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 17-12-2021
Raport public de evaluare Raport public de evaluare portugheză 31-08-2021
Prospect Prospect română 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului română 17-12-2021
Raport public de evaluare Raport public de evaluare română 31-08-2021
Prospect Prospect slovacă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 17-12-2021
Raport public de evaluare Raport public de evaluare slovacă 31-08-2021
Prospect Prospect slovenă 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 17-12-2021
Raport public de evaluare Raport public de evaluare slovenă 31-08-2021
Prospect Prospect finlandeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 17-12-2021
Raport public de evaluare Raport public de evaluare finlandeză 31-08-2021
Prospect Prospect suedeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 17-12-2021
Raport public de evaluare Raport public de evaluare suedeză 31-08-2021
Prospect Prospect norvegiană 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 17-12-2021
Prospect Prospect islandeză 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 17-12-2021
Prospect Prospect croată 17-12-2021
Caracteristicilor produsului Caracteristicilor produsului croată 17-12-2021
Raport public de evaluare Raport public de evaluare croată 31-08-2021